The IDSA has updated it’s 2004 guidelines on candidiasis (guideline). Among the highlights relevant for hospitalists: Echinocandins (caspofungin, anidulafungin, or micafungin) are recommended for treating clinically severe candidemia, empirically for all candida glabrata, and for those with recent azole use. Fluconazole can be used for clinically stable patients, or for those with confirmed sensitivities. Voriconazole is only advantageous over fluconazole in candida krusei infection, or when there is concomitant mold infection. Treatment should continue for 2 weeks after negative cultures, and intravenous catheters should be removed.
by Deepak Asudani, MD, MPH, FHM Whether it is the prompt and expeditious international collaboration to develop an Ebola vaccine, or tardy but promising development of the first anti parasitic malarial vaccine or the fascinating technology utilizing synthetic DNA for vaccine development against MERS, these developments promise to highlight significant strides in vaccine development for […]
Economists describe preferences in two ways: revealed and stated. Say, for example, I asked you to implement a penalty program for your team with the goal of decreasing the number of occasions members did not clean their hands after a patient encounter. Because you know bad hands equal bad outcomes, you’re apt to offer up […]
by Eric Howell, MD, SFHM “Tell me what you know about antibiotics.” That’s the discussion I start with hospitalized patients all the time, right after they ask me to prescribe antibiotics for their simple cough, or other viral-like illness. And, from their perspective, asking for antibiotics makes sense. After all, antibiotics have been the physician’s […]